Shenzhen Xinyuan Optical Glasses Co., Ltd. – Trademark Portfolio

Entity Type: 99

Shenzhen Xinyuan Optical Glasses Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include LEPDRITROQ. The owner is based in Shenzhen.

907 Jitong Building, No.555 Jihua Road

Shenzhen 518000 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Shenzhen Xinyuan Optical Glasses Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

9
Computers & Electronics (1 filing)

Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments

Frequently Asked Questions

How many trademarks does Shenzhen Xinyuan Optical Glasses Co., Ltd. have?

Shenzhen Xinyuan Optical Glasses Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Shenzhen Xinyuan Optical Glasses Co., Ltd. file in?

Shenzhen Xinyuan Optical Glasses Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 9 (Computers & Electronics). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.

What are Shenzhen Xinyuan Optical Glasses Co., Ltd.'s most well-known trademarks?

Shenzhen Xinyuan Optical Glasses Co., Ltd.'s registered trademark portfolio includes well-known marks such as LEPDRITROQ. These are among 1 currently registered trademark in the portfolio.

What is Shenzhen Xinyuan Optical Glasses Co., Ltd.'s trademark registration success rate?

Shenzhen Xinyuan Optical Glasses Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.